Approval · Notice of Compliance 26131 · 2021
AVAPRO: Notice of Compliance 26131
Issued June 24, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26131
- Date
- June 24, 2021
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To request for the removal of the package insert from the product packaging
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AVAPRO | Not yet assigned | — |
Medicinal ingredients
- IRBESARTAN 75 MG per TAB
- IRBESARTAN 150 MG per TAB
- IRBESARTAN 300 MG per TAB